New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...

Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

The author described in detail the vasculature of several tumours that spontaneously occur in rats, and observed that the vascular architecture of each tumour type ... of an anti-VEGF monoclonal ...

Two independent studies show that ephrin-B2 controls the internalization and signaling of two types of vascular endothelial growth factor (VEGF) receptors—thereby regulating VEGF-induced ...

Physicians’ Education Resource (PER) has launched Retina Resource, a comprehensive source of education and information on the ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

The antibody has shown promising results in preclinical studies, demonstrating 'superior' anti-tumour activity.

Older patients with diabetic macular edema have a weaker response to anti-VEGF treatment, according to a presentation at ...